Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
Subtype terms (14)
More specific conditions that are subtypes of Vasculitis in the MeSH hierarchy.
- Aortitis
- Arteritis
4 drugs (1 approved, 3 experimental)
- Behcet Syndrome
49 drugs (38 approved, 11 experimental)
- Cogan Syndrome
3 drugs approved
- IgA Vasculitis
24 drugs (21 approved, 3 experimental)
- Malignant Atrophic Papulosis
2 drugs approved
- Mucocutaneous Lymph Node Syndrome
17 drugs approved
- Phlebitis
8 drugs (5 approved, 3 experimental)
- Retinal Vasculitis
4 drugs approved
- Shwartzman Phenomenon
- Systemic Vasculitis
9 drugs (8 approved, 1 experimental)
- Thromboangiitis Obliterans
9 drugs (3 approved, 6 experimental)
- Vasculitis, Central Nervous System
10 drugs (6 approved, 4 experimental)
- Vasculitis, Leukocytoclastic, Cutaneous
10 drugs (9 approved, 1 experimental)
Drugs by status
Phase 4 trials (11)
Phase 3 trials (4)
Phase 2 trials (7)
Phase 1 trials (19)
- sodium nitrite
- tacrolimus
- Filgrastim
- aluminum hydroxide
- interleukin-10
- Anti-thymocyte Globulin (Rabbit)
- allogeneic adipose derived mesenchymal stem cell
- ama1-c1
- bone marrow derived mononuclear cells
- mesna
- vrc-wnvdna017-00-vp
- fludarabine
- agatolimod
- bcma/cd19 dual-target car-t
- cd19 car-nk cells
- stsa-1002
- impt-514
- rd06-05
- ol-108
Organizations
Organization Involved with Phase 4 Indications (31)
- Genentech
- Ocular Immunology and Uveitis Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- ZonMw: The Netherlands Organisation for Health Research and Development
- Medical Research Council
- Region Skane
- Chiba University
- University of London
- Harvard University
- Liaocheng People's Hospital
- Shandong Provincial Hospital
- Shandong Provincial Institute of Dermatology and Venereology
- University of Groningen
- University of Cambridge
- Shandong Province Qianfoshan Hospital
- Jinan University
- University of Sao Paulo
- University of Paris
- Dutch Kidney Foundation
- Dutch Arthritis Association
- Qingdao Center Medical Group
- Dongying People's Hospital, Shandong
- Shandong Jining No. 1 People's Hospital
- Dezhou People's Hospital,Shandong
- Linyi City Dermatology Hospital Prevention and Treatment
- Jining City Dermatology Hospital Prevention and Treatment
- Weifang City Dermatology Hospital Prevention and Treatment
- Laiwu City Dermatology Hospital Prevention and Treatment
- Rizhao City Dermatology Hospital Prevention and Treatment
- National Hospital Organization Chiba East Hospital
- +1 more
Organization Involved with Phase 3 Indications (35)
- Human Genome Sciences
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- ChemoCentryx
- GlaxoSmithKline
- Vifor Inc.
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pennsylvania
- Centre Hospitalier Departemental Vendee
- Johns Hopkins University
- Lund University
- University of Leicester
- University of Michigan
- University of Rochester
- University of South Florida
- University of Birmingham
- Mayo Clinic
- Assiut University
- University of Colorado, Denver
- University of Copenhagen
- Leiden University
- University of Freiburg
- University of Lyon
- Institut mutualiste, Paris, France
- French Vasculitis Study Group
- Fundació ACE
- University of Tuebingen
- Immune Tolerance Network
- +5 more
Organization Involved with Phase 2 Indications (25)
- Immunomedics
- Novartis
- Alexion
- Anthera Pharmaceuticals
- R-Pharm
- French National Agency for Research on AIDS and Viral Hepatitis
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Washington
- Indiana University
- Newcastle University
- Northwestern University
- University of Glasgow
- University of Parma
- University of Toronto
- University of California, San Francisco
- Department of Defense
- Worldwide Clinical Trials
- University of North Carolina at Chapel Hill
- Wellcome Trust
- Humboldt University
- National Center for Advancing Translational Science (NCATS)
- EUCLID
Organization Involved with Other Experimental Indications (5)